Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057954 | 0.87 | AR (0.36) | ARSQORFDPSSRC | |
| SCHEMBL1052715 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL7811159 | 0.84 | KDM4E (0.34) | SQOR | |
| SCHEMBL28046805 | 0.75 | AR (0.35) | ARFDPSSRCPOLBL3MBTL1 | |
| SCHEMBL13091993 | 0.71 | ACHE (0.39) | AR | |
| SCHEMBL4710899 | 0.71 | CYP1A2 (0.40) | — | |
| SCHEMBL1055774 | 0.71 | — | — | |
| SCHEMBL3964369 | 0.70 | KDM4E (0.35) | AR | |
| SCHEMBL18277019 | 0.70 | KDM4E (0.36) | SQOR | |
| SCHEMBL27920637 | 0.69 | HDAC3 (0.40) | SQORL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | ALK, MALT1, BCL6 | AR 1113/4885SQOR 4557/4885FDPS 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.